ATLANTA--(BUSINESS WIRE)--Jan. 10, 2006--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) have signed a three-year agreement for the distribution of HuCAL(R)-based recombinant research antibodies through Chemicon's worldwide sales network. MorphoSys's Antibodies by Design unit will develop antibodies from its proprietary HuCAL GOLD(R) antibody library against targets identified and supplied by Chemicon, a leading provider of research tools. Chemicon may market the licensed HuCAL(R)-based research antibodies for use in in vitro research as stand-alone products or as components of reagent kits. In addition, Chemicon may also market the antibodies for clinical diagnostic applications. The parties are aiming to complete 100 research antibody projects per year over the three year life time of the agreement. MorphoSys receives payment for antibody generation, optional additional fees, and royalties on all products. Further financial details were not disclosed.
